Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...
Sara Khor presents a study linking pre-diagnosis financial hardship to late-stage cancer diagnosis, drawing on SEER, TransUnion credit report, and insurance claims data from appro ...
Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. Th ...
Alicia Morgans is joined by Arnoud Templeton to discuss the REDUSE trial. This non-inferiority study compares denosumab administered every four weeks versus twelve weeks in patients with metastatic ...
Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...
The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells. July 6, 2026 Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: ...
Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract ...
First Use of the FloStent™ for Catheter-Dependent Urinary Retention Secondary to BPH: Additional Results from the RAPID I Study - Beyond the Abstract ...
Impact of Pelvic Lymph Node Dissection on Oncological Outcomes in Patients with Clinically Staged Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Systematic Review - Beyond the ...
Andrea Necchi presents GDFATHER-NEO trial results, evaluating neoadjuvant nivolumab plus visugromab versus nivolumab-placebo in 31 cisplatin-ineligible/refusing muscle-invasive bladder cancer patients ...
The Kurt extraperitoneal ligamentopexy: A new surgical method with uterine preservation for pelvic organ prolapse, "Beyond the Abstract," by Sefa Kurt and Mehmet Tunc Canda ...
(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Brian Rini discussing the 5-year analysis of KEYNOTE-426, assessing pembrolizumab + ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results